Fresenius Kabi, a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, has received the CE Mark for the Conox depth of anesthesia monitor.
Conox is a non-invasive depth of anesthesia monitor designed to help anesthesiologists monitor patient brain activity and to rapidly detect how anesthetics are affecting the patient. The Conox anesthesia monitor comprises cutting edge hardware and digital signal processing technology to measure the two main components of anesthesia: the depth of anesthesia and the patient’s reaction to external stimuli. The qCON index of hypnotic effect and the qNOX index for responsiveness are derived from one forehead sensor recording the EEG. The Conox monitor features an innovative design with easy to use graphical interface, touch screen display and easy to apply sensors.
Conox was developed by Barcelona-based Quantium Medical S.L.U., which was acquired by Fresenius Kabi last year. Quantium Medical is a dynamic company focused on the development of non-invasive physiological monitoring and biosignal data processing.
“Quantium Medical’s non-invasive monitoring competence is an excellent fit for Fresenius Kabi with its anesthetics I.V. drugs and infusion technology. The new Conox device will provide high-quality anesthesia monitoring and enhance our solution offering in the operating room and intensive care units,” said Dr. Christian Hauer, President, Medical Devices Division, Fresenius Kabi.
”The acquisition opens a lot of opportunities for Quantium Medical and the employees of the company to bring world class science into innovative medical products with solutions previously unheard-of,” said Erik Weber Jensen, CEO of Quantium Medical
Fresenius Kabi expects to begin offering the Conox monitor in February 2017.
For questions please contact:
Name: Rebecca Zhou
Phone: (+34) 702 19 50
About Fresenius Kabi:
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. For more information, please visit www.fresenius-kabi.com.